Nothing Special   »   [go: up one dir, main page]

DK2993170T3 - N-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamidderivater som aldh-2- hæmmere til behandling af afhængighed - Google Patents

N-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamidderivater som aldh-2- hæmmere til behandling af afhængighed

Info

Publication number
DK2993170T3
DK2993170T3 DK15184883.5T DK15184883T DK2993170T3 DK 2993170 T3 DK2993170 T3 DK 2993170T3 DK 15184883 T DK15184883 T DK 15184883T DK 2993170 T3 DK2993170 T3 DK 2993170T3
Authority
DK
Denmark
Prior art keywords
dependence
treatment
aldh
pyridin
dihydro
Prior art date
Application number
DK15184883.5T
Other languages
English (en)
Inventor
Michael Graupe
Juan A Guerrero
Robert G Stickley
Chandrasekar Venkataramani
Jeff Zablocki
Carina E Cannizzaro
Yafan Lu
Original Assignee
Amygdala Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amygdala Neurosciences Inc filed Critical Amygdala Neurosciences Inc
Application granted granted Critical
Publication of DK2993170T3 publication Critical patent/DK2993170T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/58Pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK15184883.5T 2011-07-01 2012-06-29 N-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamidderivater som aldh-2- hæmmere til behandling af afhængighed DK2993170T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161503923P 2011-07-01 2011-07-01
EP12735394.4A EP2726460B1 (en) 2011-07-01 2012-06-29 Compounds for the treatment of addiction

Publications (1)

Publication Number Publication Date
DK2993170T3 true DK2993170T3 (da) 2018-01-29

Family

ID=46513858

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15184883.5T DK2993170T3 (da) 2011-07-01 2012-06-29 N-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamidderivater som aldh-2- hæmmere til behandling af afhængighed

Country Status (33)

Country Link
US (6) US8558001B2 (da)
EP (2) EP2726460B1 (da)
JP (1) JP5943998B2 (da)
KR (2) KR101664915B1 (da)
CN (1) CN103635460B (da)
AP (1) AP3544A (da)
AR (1) AR086792A1 (da)
AU (1) AU2012279332B2 (da)
BR (1) BR112014000033A2 (da)
CA (1) CA2840763C (da)
CL (1) CL2013003597A1 (da)
CO (1) CO6821964A2 (da)
CR (1) CR20130659A (da)
DK (1) DK2993170T3 (da)
EA (1) EA025573B1 (da)
EC (1) ECSP13013087A (da)
ES (2) ES2656716T3 (da)
HK (2) HK1197236A1 (da)
IL (1) IL230657B (da)
MA (1) MA35404B1 (da)
MD (1) MD4436B1 (da)
MX (1) MX337611B (da)
PE (1) PE20141067A1 (da)
PH (1) PH12013502674A1 (da)
PL (1) PL2726460T3 (da)
PT (1) PT2726460E (da)
SG (1) SG10201605355RA (da)
SI (1) SI2726460T1 (da)
TW (1) TWI567061B (da)
UA (1) UA109199C2 (da)
UY (1) UY34165A (da)
WO (1) WO2013006400A1 (da)
ZA (1) ZA201308977B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
NZ617987A (en) 2011-05-10 2016-02-26 Gilead Sciences Inc Fused heterocyclic compounds as sodium channel modulators
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (da) 2011-07-01 2018-04-28
EP2970124B1 (en) 2013-03-14 2019-05-22 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CA2931550C (en) * 2013-12-13 2023-09-26 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
US10077669B2 (en) 2014-11-26 2018-09-18 United Technologies Corporation Non-metallic engine case inlet compression seal for a gas turbine engine
US10289971B2 (en) 2015-02-13 2019-05-14 Atlassian Pty Ltd Issue and trigger rebalancing in a ranked issue management system
HRP20221497T1 (hr) 2016-08-19 2023-02-17 The University Of Bristol Derivati citizina za liječenje ovisnosti
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
AU2018352215A1 (en) * 2017-10-16 2020-04-16 Amygdala Neurosciences, Inc. Combination therapy for preventing addiction
IL300572A (en) 2018-02-13 2023-04-01 Gilead Sciences Inc PD–1/PD–L1 inhibitors
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
SG11202010964VA (en) 2018-05-14 2020-12-30 Gilead Sciences Inc Mcl-1 inhibitors
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
WO2020023792A1 (en) * 2018-07-27 2020-01-30 Amygdala Neurosciences, Inc. Combination therapy for nicotine addiction
WO2020076974A1 (en) * 2018-10-12 2020-04-16 Amygdala Neurosciences, Inc. Addiction treatment of an alcohol-consuming patient population
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US12018009B2 (en) 2022-06-14 2024-06-25 Amygdala Neurosciences, Inc. ALDH-2 inhibitor compounds and methods of use
WO2023244563A1 (en) 2022-06-14 2023-12-21 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5204369A (en) 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
WO1999058124A1 (en) 1998-05-12 1999-11-18 The Endowment For Research In Human Biology, Inc. Methods and assays useful in the treatment of alcohol dependence or alcohol abuse
MXPA05000122A (es) * 2002-06-27 2005-12-14 Endowment For Res In Human Bio Compuestos utiles para la inhibicion de aldehido-deshidrogenasa.
JP2004182657A (ja) * 2002-12-04 2004-07-02 Eisai Co Ltd Hdlレベル上昇促進剤
US20080004260A1 (en) 2006-06-29 2008-01-03 Transcept Pharmaceuticals, Inc. Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions
US8158810B2 (en) 2006-07-27 2012-04-17 Gilead Sciences, Inc. ALDH-2 inhibitors in the treatment of addiction
MX2008015765A (es) 2006-07-27 2009-03-26 Cv Therapeutics Inc Inhibidores de aldh-2 en el tratamiento de adiccion.
US20080207610A1 (en) 2006-07-27 2008-08-28 Jeff Zablocki Aldh-2 inhibitors in the treatment of addiction
CA2679882C (en) 2007-03-08 2015-12-29 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
EP2254878A1 (en) 2008-01-24 2010-12-01 Gilead Palo Alto, Inc. Aldh-2 inhibitors in the treatment of addiction
TW200946520A (en) 2008-05-01 2009-11-16 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CN102209541B (zh) 2008-09-08 2016-05-18 小利兰·斯坦福大学托管委员会 醛脱氢酶活性调节剂和其使用方法
JP2012506856A (ja) * 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
UY33469A (es) * 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物

Also Published As

Publication number Publication date
UY34165A (es) 2013-01-31
PH12013502674A1 (en) 2014-02-10
AR086792A1 (es) 2014-01-22
WO2013006400A1 (en) 2013-01-10
PE20141067A1 (es) 2014-09-05
HK1217487A1 (zh) 2017-01-13
US20130005689A1 (en) 2013-01-03
US20170266210A1 (en) 2017-09-21
EA025573B1 (ru) 2017-01-30
MX337611B (es) 2016-03-10
ZA201308977B (en) 2014-08-27
MD20140009A2 (ro) 2014-06-30
ES2553829T3 (es) 2015-12-14
EP2726460A1 (en) 2014-05-07
KR20160106207A (ko) 2016-09-09
CN103635460B (zh) 2016-03-16
MX2013014938A (es) 2014-04-30
US8558001B2 (en) 2013-10-15
US10507215B2 (en) 2019-12-17
US9000015B2 (en) 2015-04-07
AP3544A (en) 2016-01-14
AP2013007282A0 (en) 2013-11-30
TW201307288A (zh) 2013-02-16
NZ618537A (en) 2016-03-31
IL230657A0 (en) 2014-03-31
UA109199C2 (uk) 2015-07-27
SG10201605355RA (en) 2016-08-30
CA2840763C (en) 2019-09-10
PL2726460T3 (pl) 2016-03-31
KR101664915B1 (ko) 2016-10-11
JP5943998B2 (ja) 2016-07-05
US20150250805A1 (en) 2015-09-10
IL230657B (en) 2018-02-28
US20180338989A1 (en) 2018-11-29
US9610299B2 (en) 2017-04-04
ECSP13013087A (es) 2014-01-31
US20130203704A1 (en) 2013-08-08
MD4436B1 (ro) 2016-09-30
US8575353B2 (en) 2013-11-05
EP2726460B1 (en) 2015-09-23
AU2012279332A1 (en) 2013-04-04
KR20140042884A (ko) 2014-04-07
AU2012279332B2 (en) 2015-02-05
EP2993170B1 (en) 2017-10-25
US20140051668A1 (en) 2014-02-20
CO6821964A2 (es) 2013-12-31
US9987295B2 (en) 2018-06-05
CA2840763A1 (en) 2013-01-10
TWI567061B (zh) 2017-01-21
ES2656716T3 (es) 2018-02-28
HK1197236A1 (en) 2015-01-09
CR20130659A (es) 2014-02-18
EA201391635A1 (ru) 2014-04-30
MA35404B1 (fr) 2014-09-01
CL2013003597A1 (es) 2014-06-13
CN103635460A (zh) 2014-03-12
PT2726460E (pt) 2015-12-07
EP2993170A1 (en) 2016-03-09
SI2726460T1 (sl) 2015-11-30
JP2014520809A (ja) 2014-08-25
BR112014000033A2 (pt) 2019-06-18

Similar Documents

Publication Publication Date Title
DK2993170T3 (da) N-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamidderivater som aldh-2- hæmmere til behandling af afhængighed
WO2008145688A3 (en) Pyrrolopyridine compounds, process for their preparation, and their use as medicaments
EA201491824A1 (ru) Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
WO2008132600A3 (en) Trpv1 antagonists and uses thereof
TW200716107A (en) Polymorphs of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
BR112015021983A8 (pt) compostos heterocíclicos, composições e usos dos mesmos
BR112015001608A2 (pt) inibidor lfa-1 e polimorfo do mesmo
UA109792C2 (uk) Індоли як противірусні агенти відносно респіраторного синтиціального вірусу
SMT201300098B (it) Forme solide di N-(4-(7-azabiciclo[2.2.1]eptan-7-il)-2-(trifluorometil)fenil-4-osso-5-trifluorometil)-1,4-diidrochinolina-3-carbossammide
WO2010021680A3 (en) Inhibitors of beta-secretase
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
BRPI0813499B8 (pt) compostos pirimidina carboxamidas úteis como inibidores da quinase raf, composição farmacêutica compreendendo os mesmos e método de preparação dos mesmos
WO2011110876A8 (en) Novel salts for the manufacture of pharmaceutical compositions
WO2012113873A3 (en) Organic compounds
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
ATE500222T1 (de) Benzamid- und heteroarenderivate als cetp- inhibitoren
WO2013012485A3 (en) Novel crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
EA201201082A1 (ru) Фармацевтическая композиция, содержащая n-(2-хлор-6-метилфенил)-2-[[6-[4-(2-гидроксиэтил)-1-пиперазинил]-2-метил-4-пиримидинил]амино]-5-тиазолкарбоксамид
WO2013150545A3 (en) Process for preparation of benzimidazole derivatives and salts thereof
UA112556C2 (uk) Інсектицидні похідні 2-метоксибензамідів
EP2585446A4 (en) COMPOUNDS WITH ANTAGONISTIC EFFECT AGAINST TRPV1 AND THEIR USE
WO2014057080A3 (en) N-(2-(cyclic amine)ethyl)benzamide derivatives as p2x7 inhibitors
WO2009145591A3 (en) Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof
PH12014501181A1 (en) N- (4 -quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics
EA201791321A1 (ru) Составы ингибитора lfa-1